anti-TRAIL-R2 (human) mAb (HS201) (ATTO 647N)
| Code | Size | Price |
|---|
| AG-20B-0023TS-T100 | 100 tests | £330.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: HS201
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Immunocytochemistry (ICC)
Shipping:
+4°C
Storage:
4°C
Documents
Further Information
Alternate Names/Synonyms:
TRAIL Receptor 2; DR5; KILLER; TNFRSF10B; CD262
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 0.02% sodium azide.
Handling Advice:
Do not freeze.Protect from light.
Immunogen:
Recombinant human TRAIL-R2 (DR5).
Labels - Conjugates:
ATTO 647N
Long Description:
Monoclonal Antibody. Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4. Isotype: Mouse IgG1. Clone: HS201. Applications: FACS, ICC. Liquid. In PBS containing 0.02% sodium azide. TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappaB.
NCBI, Uniprot Number:
O14763
Other data:
New ATTO-fluorescent antibodies show increased photostability, outstanding brightness and intense signals. ATTO dyes are thermally stable, resistant to environmental changes and show no significant isomerization. ATTO 647N shows red fluorescence (lambdaabs (max): 645nm, lambdaem (max): 669nm, epsilonmax: 120?000).
Package Type:
Plastic Vial
Product Description:
TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappaB.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibody Conjugates
UNSPSC Number:
12352203
Use & Stability:
Keep conjugated formats at +4°C. Stable for at least 1 year after receipt when stored at +4°C.
References
Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8: M.R. Sprick, et al.; EMBO J. 21, 4520 (2002) | Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8: T.S. Soderstrom, et al.; J. Immunol. 169, 2851 (2002) | Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis: H. Higuchi, et al.; J. Biol. Chem. 278, 454 (2003) | Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation: M. Leverkus, et al.; Mol. Cell. Biol. 23, 777 (2003) | TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol. 170, 1814 (2003) | Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ. 11 Suppl 1, 86 (2004) | Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex: K. Izeradjene, et al.; Cancer Res. 64, 8036 (2004) | Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5: T.G. Jin, et al.; J. Biol. Chem. 279, 55594 (2004) | TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood 103, 517 (2004) | IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells: C. Tecchio, et al.; Blood 103, 3837 (2004) | cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem. 279, 52824 (2004) | Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood 111, 4780 (2008) | TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells: M.H. Tuthill, et al.; Oncogene 34, 2138 (2015)